Olema Pharmaceuticals, Inc. (OLMA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-93.1%

$0.49

vs $7.07 price

Levered DCF

$0.54

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

4.21

Safe zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-13.37×	-2.65×	-6.56×	-0.94×	-5.23×	-82.9×	-445.45×	-306.25×
P/B	4.55×	0.84×	2.5×	0.5×	1.3×	5.59×	-185.8×	-110.04×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-13.14×	-1.58×	-5.91×	-0.74×	-5.07×	-72.1×	-456.99×	-332.05×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	9.95×	10.5×	12.33×	12.62×	32.23×	74.62×	0.07×	16.13×
Debt / equity	0×	0×	0.01×	0.01×	0.01×	0×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	-32.97×	0×	-74.25×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-33.9%	-31.7%	-38.1%	-53.0%	-25.0%	-6.5%	40.7%	35.0%
Return on invested capital	-37.0%	-34.7%	-41.0%	-53.5%	-24.8%	-6.4%	347.0%	-67.7%
Return on assets	-30.5%	-28.7%	-34.9%	-48.6%	-24.0%	-6.5%	-3269.7%	-67.2%
Free cash flow yield	-6.7%	-30.5%	-13.2%	-84.1%	-14.1%	-1.1%	-0.2%	-0.3%
Earnings yield	-7.5%	-37.8%	-15.2%	-106.9%	-19.2%	-1.2%	-0.2%	-0.3%
Enterprise value	$2.1B	$204.4M	$568.7M	$76.9M	$359.4M	$1.6B	$2B	$687.7M
Net debt / EBITDA	0.29×	1.07×	0.69×	0.2×	0.15×	15.73×	0.02×	1.52×
Cash conversion cycle (days)	0	0	0	0	0	-23,858	-37,781	-5,136